Skip to content
Orantinib
Orantinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2. In addition, it is known to target epidermal growth factor receptor and fibroblast growth factor receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver neoplasmsD008113EFO_1001513C22.0111——2
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801————1
Prostatic neoplasmsD011471C611————1
Colorectal neoplasmsD0151791————1
Breast neoplasmsD001943EFO_0003869C501————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
Stomach neoplasmsD013274EFO_0003897C161————1
Lung neoplasmsD008175C34.901————1
Plasma cell neoplasmsD0542191————1
Kidney neoplasmsD007680EFO_0003865C641————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameORANTINIB
INNorantinib
Description
Orantinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2. In addition, it is known to target epidermal growth factor receptor and fibroblast growth factor receptor 1.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Identifiers
PDB—
CAS-ID1044712-39-1
RxCUI—
ChEMBL IDCHEMBL274654
ChEBI ID—
PubChem CID5329099
DrugBank—
UNII ID9RL37ZZ665 (ChemIDplus, GSRS)
Target
Agency Approved
PDGFRB
PDGFRB
KDR
KDR
Organism
Homo sapiens
Gene name
PDGFRB
Gene synonyms
PDGFR, PDGFR1
NCBI Gene ID
5159
Protein name
platelet-derived growth factor receptor beta
Protein synonyms
Activated tyrosine kinase PDGFRB, Beta platelet-derived growth factor receptor, Beta-type platelet-derived growth factor receptor, CD140 antigen-like family member B, CD140b, NDEL1-PDGFRB, PDGF-R-beta, PDGFR-1, PDGFR-beta, Platelet-derived growth factor receptor 1, platelet-derived growth factor receptor, beta polypeptide
Uniprot ID
Q8N5L4
Mouse ortholog
Pdgfrb (18596)
platelet-derived growth factor receptor beta (P05622)
Alternate
EGFR
EGFR
FGFR1
FGFR1
Organism
Homo sapiens
Gene name
EGFR
Gene synonyms
ERBB, ERBB1, HER1
NCBI Gene ID
1956
Protein name
epidermal growth factor receptor
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, EGFR vIII, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Uniprot ID
Q9UMG5
Mouse ortholog
Egfr (13649)
epidermal growth factor receptor (Q01279)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 173 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details